Clinical outcomes in sensitized heart transplant patients bridged with ventricular assist devices

Clinical Transplantation

Volumn 29, Issue 6, 2015, Pages 499-505

  Kidambi, Sumanth ^a   Mohamedali, Burhan ^b   Bhat, Geetha ^a  

^a ADVOCATE CHRIST MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY   (United States)

Author keywords

Acute cellular rejection; Allosensitization; Antibody mediated rejection; Bridge to transplant; Heart transplant; Infection; Left ventricular assist device; Mechanical support; Mortality; Orthotopic heart transplant; Outcomes; Panel reactive antibody

Indexed keywords

PANEL REACTIVE ANTIBODY; ALLOANTIBODY; BIOLOGICAL MARKER; HLA ANTIGEN;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIBODY MEDIATED REJECTION; ARTICLE; BLOOD PUMP; CARDIAC PATIENT; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART GRAFT; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LEFT VENTRICULAR ASSIST DEVICE; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SENSITIZATION; ADVERSE EFFECTS; BLOOD; EVALUATION STUDY; GRAFT REJECTION; HEART ASSIST DEVICE; HEART TRANSPLANTATION; IMMUNOLOGY; MIDDLE AGED; MORTALITY;

ADULT; BIOMARKERS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84930821802     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12540     Document Type: Article

References (23)

1. Butler CR, Jugdutt BI. Mechanical circulatory support for elderly heart failure patients. Heart Fail Rev 2012: 17: 663.
2. Itescu S, John R. Interactions between the recipient immune system and the left ventricular assist device surface: immunological and clinical implications. Ann Thorac Surg 2003: 75: S58.
3. Drakos SG, Kfoury AG, Kotter JR et al. Prior HLA-allosensitization and left ventricular assist device type affect degree of post-implantation HLA-allosensitization. J Heart Lung Transplant 2009: 28: 838.
4. Kobashigawa JA, Sabad A, Drinkwater D et al. Pretransplant panel reactive antibody screens. Are they truly a marker for poor outcome after cardiac transplantation? Circulation 1996: 94: II294.
5. De Mattos AM, Head MA, Everett J et al. HLA-DR mismatching correlates with early cardiac allograft rejection, incidence, and graft survival when high-confidence-level serological DR typing is used. Transplantation 1994: 57: 626.
6. Lavee J, Kormos RL, Duquesnoy RJ et al. Influence of panel reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. J Heart Lung Transplant 1991: 10: 921.
7. Urban M, Gazdic T, Slimackova E et al. Alloimmunosensitization in left ventricular assist device recipients and impact on posttransplantation outcome. ASAIO J 2012: 58: 554.
8. Shankar N, Daly R, Geske J et al. LVAD implant as a bridge to heart transplantation is associated with allosensitization as measured by single antigen bead assay. Transplantation 2013: 96: 324.
9. Massad MG, Cook DJ, Schmitt SK et al. Factors influencing HLA sensitization implantable LVAD recipients. Ann Thorac Surg 1997: 64: 1120.
10. Gonzalez-Stawinski G, Cook D, Chui J et al. A comparative analysis between survivors and nonsurvivors with antibody mediated cardiac allograft rejection. J Surg Res 2007: 142: 233.
11. Ho EK, Vlad G, Coloval AI et al. Alloantibodies in heart transplantation. Hum Immunol 2009: 70: 825.
12. Costanzo MR, Dipchand A, Starling R et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010: 29: 914.
13. Sis B, Mengel M, Haas M et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010: 10: 464.
14. Stringham JC, Love RB, Welter D, Canver CC, Mentzer RM Jr. Does University of Wisconsin solution harm the transplanted heart? J Heart Lung Transplant 1999: 18: 587.
15. Drakos SG, Stringham JC, Long JW et al. Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: the impact of leukofiltered cellular blood product transfusions. J Thorac Cardiovasc Surg 2007: 133: 1612.
16. McKenna DH Jr., Eastlund T, Segall M, Noreen HJ, Park S. HLA alloimmunization in patients requiring ventricular assist device support. J Heart Lung Transplant 2002: 21: 1218.
17. Itescu S, Ankersmit JH, Kocher AA, Schuster MD. Immunobiology of left ventricular assist devices. Prog Cardiovasc Dis 2000: 43: 67.
18. Itescu S, Tung TC, Burke EM et al. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation 1998: 98: 786.
19. Schuster M, Kocher AA, John R et al. Allosensitization following left ventricular assist devices (LVAD) implantation is dependent on CD40-CD40 ligand interactions. J Heart Lung Transplant 2001: 20: 211.
20. George I, Colley P, Russo MJ et al. Association of device surface and biomaterials with immunologic sensitization after mechanical support. J Thorac Cardiovasc Surg 2008: 135: 1372.
21. Healy AH, Mason NO, Hammond ME et al. Allograft rejection in patients supported with continuous-flow left ventricular assist devices. Ann Thorac Surg 2011: 92: 1601; discussion 1607.
22. Pagani FD, Dyke DB, Wright S et al. Development of anti-major histocompatibility complex class I or II antibodies following left ventricular assist device implantation: effects on subsequent allograft rejection and survival. J Heart Lung Transplant 2001: 20: 646.
23. Pamboukian SV, Costanzo MR, Dunlap S et al. Relationship between bridging with ventricular assist device on rejection after heart transplantation. J Heart Lung Transplant 2005: 24: 310.